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outcome, percentage of days in which all procedures were completed within the 
scheduled OR day, was higher in the OR using sugammadex (79.8%) compared to 
the OR using neostigmine (40.7%) [range for sugammadex values was 40.7% to 
93.1% in the exploratory analyses]. Base-case total overtime over a one-month 
period was less with sugammadex use compared to neostigmine use (3.6 and 15.0 
hours, respectively). ConClusions: Even relatively modest reductions in proce-
dure times with use of sugammadex for NMB reversal might lead to meaningful 
improvement in OR efficiency and reduced overtime.
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objeCtives: To determine the positive recommendation rate for combination 
drugs under the CDR. Methods: In Canada, eligible non-cancer prescription 
drugs approved by Health Canada (including combination drugs) are reviewed by 
the Common Drug Review (CDR) process that is part of the Canadian Agency for 
Drugs and Technologies in Health (CADTH). The CDR makes reimbursement rec-
ommendations that are considered by provincial and federal plans in making their 
formulary coverage decisions. The majority of the combination drugs consist of 
individual components that are currently available in the market. The advantages 
to combination drugs are several, including reduced dispensing fees, reduced pill 
burden and possibly synergistic effect. CDR-reviewed combination drugs in our 
proprietary CDR Tracker®database were analyzed. Results: 33 unique combina-
tion drugs with 36 submissions have been reviewed by the CDR. The positive rec-
ommendation (List; List in a similar manner; List with criteria; List with criteria/
condition) rate of these 36 submissions were 64% (23 of 36). This is higher than the 
average CDR positive recommendation rate for all drugs of 54%. ConClusions: 
The high positive recommendation rate for combination drugs may be reflective of 
the various clinical and economic advantages of this drug class.
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objeCtives: In addition to Canadian Drug Review (CDR), an independent, prov-
ince-driven mechanism is now in place known as Pan Canadian Pricing Alliance 
(pCPA). The purpose of this virtual committee is to conduct joint provincial / 
territorial negotiations for brand name drug products when appropriate. Since 
this initiative was announced by Premiers in August 2010, the implication of this 
initiative has yet to be measured. This paper quantifies the impact of pCPA by 
comparing the ‘days to listing’ and longitudinally assessing data between 2008 
and 2013. Methods: Using publically accessible CDR data, IMS Brogan applied 
selection criteria to identify drugs for analysis including: Tracked all drugs post 
CDR recommendation (made through 2008 – 2012) for a duration of 18 months, 
and the Used Ontario Public Drug Plan (OPDP), except Quebec, the leading province 
of listing new products in the Formulary, as a representative to measure time 
from CDR recommendation to formulary listing. Selection criteria were rigorous 
to ensure credible results; the resulting sample size was n= 103. If a drug was 
reviewed for multiple indications, it was given an additional weight based of the 
number of indications. Results: Findings revealed that, although pCPA is an 
added layer to the public listing in the Canadian health care system, time to listing 
has continued to decrease. The average time to listing for drugs reviewed in 2012 
was185 days, a 33% decrease compared to 2008. Further analysis assessed median 
and minimum days to listing, which further supported this trend. ConClusions: 
The recent trends show time to listing of new products on the OPDP Formulary 
has been decreasing; pCPA does not delay the listing process. Future trends could 
not be ascertained due to data horizon length.
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objeCtives: The objective of this study was to evaluate the decisions provided 
by the National Commission for Health Technology Incorporation (CONITEC) from 
the Brazilian public health care system (SUS) submitted from January 2011 until 
September 2013. Methods: All the submissions to CONITEC were evaluated based 
on the data available at the Ministry of Health website. The submissions were cat-
egorized by the type of submission (inclusion or exclusion), type of applicant (public 
body or external) and type of technology (drug, health product or procedure). The 
status of each submission requesting the incorporation of a new technology was 
analyzed and the success rate of the submissions was calculated as the number 
of incorporations divided by the number of submissions. Results: A total of 276 
submissions were done to CONITEC and 261 of those (95%) required the incorpora-
tion of a new health technology. Among the incorporation submissions, 64% were 
related to drugs, 20% to procedures and 16% to health products. Forty six per cent 
of those submissions were done by public bodies. The status of the submissions 
in September 2013 was: 56 positive decisions for incorporation (22%), 39 negative 
decisions (15%), 99 submissions under evaluation (38%), 55 submissions denied for 
failure to comply with CONITEC requirements (21%), 5 submissions terminated at 
the request of the company (1.9%), 6 submissions considered outside the scope 
of CONITEC (2.3%) and 1 technology already incorporated by SUS (0.4%). The suc-
cess rate of the submissions done by public bodies was 33% and 11% for external 
submissions. ConClusions: The rate of technologies incorporated by CONITEC 
was higher than the rate of negative decisions but the success rate is still limited. 
Most submissions are still under evaluation and the rate of submissions considered 
incompliant was high, showing that there’s a learning process to comply with the 
new CONITEC requirements.
objeCtives: Disease-related malnutrition (DRM) is not confined to develop-
ing countries and remains a significant cause of diseases and deaths worldwide. 
Present in all health care settings DRM is often unrecognized and untreated. Despite 
information on DRM prevalence and clinical outcomes, there is comparatively lit-
tle information on its economic impact. This study reviewed the assessment of 
DRM and associated economic burden in different geographic regions. Methods: 
A comprehensive literature review was undertaken for all publications from 1998 
to July 2013 using Medline, EMBASE, Cochrane, HEED databases. Search completed 
for English and non-English (German, Spanish, Italian, French, and Arabic) articles. 
Articles were systematically selected if they presented data for hospitalized patients 
on at least one of the following: DRM, epidemiology, costs, treatment options, clini-
cal outcomes. Results: Database search yielded 12,570 articles and 60 additional 
articles were identified via secondary hand searches. Of the 167 eligible articles; 42 
provided information on DRM definition, screening and treatment guidelines, 29 
on epidemiological data, 38 on clinical outcomes, and 17 on cost. Most screening 
tools incorporated recent weight loss, food intake, and disease severity. Prevalence 
estimates varied greatly within and by region; US (1%-54%), Europe (2.5%-86%), Asia 
(12%-55.2%), Latin America (34.8% - 78.8%), and Canada (31%-69%). Malnourished 
patients compared to well-nourished patients experienced longer hospital stay 
(additional days between 1.6 and 6.6) and higher costs per hospital stay (19%-54.9%). 
Malnourished patients in the US, Europe, Asia, and Latin America incurred costs 
between USD$21900-$66700, EUR€ 4890-€ 12237, SGD$4606, and BRL$3807, respec-
tively. ConClusions: DRM assessment and prevalence varies greatly due to the 
disparate malnutrition definition and screening criteria. Broad estimates of the 
financial burden exist in some countries however the validity of some estimates is 
poor and lack generalizability. Health economic research is needed to address the 
present scarcity of data necessary to fully characterize the financial burden of DRM.
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objeCtives: To determine the types of medication-related interventions, and 
attendant resolution rates associated with telephonic versus in-person medica-
tion therapy management (MTM) consults. Methods: A retrospective review of 
electronic medical records and prescription claims data was conducted. Patients 
with one consult between January 1st and May 31st2013 were included; the date of 
the consult was defined as the index date. Data regarding intervention resolution 
was collected within 6 months post index. Inclusion criteria: one MTM consult with 
a Scott & White pharmacist within the study period. Exclusion criteria: multiple 
consults within the study period. Interventions regarding non-prescription medi-
cations and medication coupon use were excluded from outcomes reporting. Each 
intervention was grouped into 1 of 5 categories: cost, safety and efficacy, preventa-
tive therapy, education, and vaccination. Chi squared analyses were used to detect 
significant differences at a p-value of 0.05. Results: Forty-three patients and 105 
patients were identified in the in-person and telephonic consult groups respectively. 
Among patients who received in-person consults, the majority of interventions were 
related to education (35%), cost (26%), and safety and efficacy (22%). Interventions 
related to education (21%), cost (33%), and safety and efficacy (25%) also comprised 
the majority of interventions in the telephonic consult setting. There were no signifi-
cant differences detected, between groups, in the types of interventions occurring 
in each setting. The acceptance rate of vaccine related interventions was greater 
in the in-person consult group when compared to the telephonic consult group 
(p= 0.02). There were no significant differences observed in the acceptance rates of 
interventions regarding cost, safety and efficacy, preventative therapy, and educa-
tion. ConClusions: While there were no statistically significant differences in 
acceptance rates associated with education, cost, and safety and efficacy, the results 
of this study suggest that interventions related to vaccination are more likely to be 
accepted when made in person.
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bloCkaDE: a DisCrEtE EVEnt simulation moDEl oF oPErating room 
EFFiCiEnCy in CanaDa
Goyette A.1, Insinga R.P.2, Galarneau A.1, Maiese E.M.3
1Merck Canada Inc., Kirkland, QC, Canada, 2Merck & Co. Inc., Upper Gwynedd, PA, USA, 3Merck & 
Co, Inc., Whitehouse Station, NJ, USA
objeCtives: Sugammadex significantly shortens time and variability to recov-
ery from neuromuscular blockade (NMB) compared to neostigmine. Our objective 
is to explore the potential impact on operating room (OR) efficiency with use 
of sugammadex versus neostigmine for NMB reversal in Canada. Methods: A 
discrete event simulation (DES) model was developed to compare two OR suites, 
one using neostigmine and the other sugammadex. The same OR parameters, 
including OR day start and end time, time to start first surgery, and time between 
surgeries, are shared by the two ORs. The same surgeries are scheduled in the 
two ORs. In the OR using sugammadex, a reduction in OR time per procedure is 
applied. Base-case time reductions (17.1 minutes) are derived from a head-to-head 
randomized controlled trial where tracheal extubation occurs when the patient 
achieves the recommended recovery of a Train-of-Four (TOF) ratio ≥ 0.9. In real-
life, patients, however, may be extubated irrespective of recovering to a TOF ratio 
≥ 0.9; therefore, exploratory analyses were also conducted with a range of values 
(0 to 25 minute reductions) for potential time savings with sugammadex. The 
model can also consider reduction in variability of OR time with sugammadex 
use. During each run, the model calculates a value for each parameter according 
to a statistical distribution. Results: For the base-case analysis, the primary 
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of IRP reforms as we found that even small changes to reference baskets used in 
IRP can lead to large negative financial impacts for pharmaceutical manufactures.
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objeCtives: In most western countries it is a prerequisite before a new drug is 
approved into the reimbursement system that its cost-effectiveness has been dem-
onstrated. The pricing authorities’ assessment of the cost-effectiveness is usually 
based on a health economic evaluation required from the applicant. In Finland 
these evaluations have been obligatory since 1998. The objective of this study is to 
assess the present quality of these economic evaluations. Methods: This study 
is based on a random sample of 13 economic evaluations submitted with price 
applications in Finland in 2012. These evaluations were assessed using a structured 
questionnaire with 25 different items. The items assessed include e.g. the choice 
of comparator, the method of analysis, the structure of the model, the estimation 
costs and health effects and the assessment of uncertainty. Results: Only two of 
the 13 evaluations were reliable enough for their results to be used as such in the 
pricing and reimbursement decision. In seven evaluations the results were of some 
use in the decision making. Among the reasons limiting their usefulness were that 
they contained uncertain assumptions, that some costs items were excluded from 
the analysis, and that the effectiveness of the treatments was based mainly on 
assumptions. Four economic evaluations could not be used in the decision making 
at all because the comparator was wrong, the effectiveness estimates were biased, 
or there was a lot of uncertainty attached to the key parameters (effectiveness, 
quality of life and costs). ConClusions: There is still much to be improved in 
the quality of the submitted economic evaluations. This need for improvements is 
highlighted by the fact that the era of prolonged austerity has made it all the more 
important that only drugs with an acceptable cost-effectiveness ratio are accepted 
into the reimbursement system.
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objeCtives: To assess the effects of policy and institutional changes on the total 
Time to Reimbursement (tTTR) of innovative pharmaceutical products in Canada. 
Such changes include: the removal of criteria for “pre-NOC” drugs; queuing at CDR 
as its capacity to process submissions is stretched; and the emergence of the pan-
Canadian Pricing Alliance (pCPA), which negotiates with manufacturers on behalf 
of drug plans. Methods: Using our proprietary CDR Tracker® database we assessed 
the tTTR, i.e. time from receipt of Notice of Compliance (NOC) to provincial reim-
bursement, for all CDR-reviewed drugs reimbursed by the Ontario Public Drug Plan. 
We separately examined the responsibilities of pharma manufacturers, CDR and 
the provinces themselves. We analyzed the Time to Submission, (TTS), i.e. NOC date 
to CDR submission date, Time to Recommendation (TTRec), i.e. CDR submission 
date to CDR recommendation date, and the Time to Decision (TTD) by the drug 
plan, i.e. recommendation date to Ontario formulary decision date. We assessed 
the tTTR for each year of CDR’s existence to identify changes of importance to 
manufacturers. Results: Removal of criteria for pre-NOC submissions increased 
their number: 17 pre-NOC submissions have occurred in months since the policy 
change, compared to 4 in total previously. Average TTS fell from 217 days to 151 days 
for drugs submitted before and after the change. TTRec prior to the queuing period 
was 203 ± 40 days. Since queuing was introduced this has increased to 214 ± 18 days. 
TTD has steadily declined over time and sharply since the arrival of pCPA. tTTR 
rose steadily from the beginning of CDR and fell sharply with the introduction of 
pCPA. ConClusions: pCPA and CDR’s efforts have attentuated the consequences 
of queuing so far, though the full effect of the large and growing number of drugs 
currently in queue at CDR remains to be seen.
PHP93
bEnEFit DEsign CHangE in a CommErCially insurED Continuously 
EnrollED PoPulation
Su W.1, Carlson A.1, Hedin C.2
1University of Minnesota, minneapolis, MN, USA, 2Prime Therapeutics, minneapolis, MN, USA
objeCtives: Numerous studies have examined prescription utilization and medi-
cation adherence using continuous enrollment criteria with claims data. Benefit 
design changes may have an impact on both measures. The purpose of this analysis 
was to indentify the multiple changes of benefit plan designs that occurred in a 
commercially insured population continuously enrolled for 30 months. Methods: 
Retrospective study examining eligibility data and health plan benefit design 
records. Commercially insured beneficiaries aged 18 or older and enrolled from 
January 1st, 2011 through June 30th, 2013 were included. The benefit designs for 
all beneficiaries were identified from administrative records. Results: 2,489,106 
beneficiaries met enrollment criteria. Approximately 12% (289,159 beneficiaries) 
experienced at least one change in retail, mail, or Extended Supply Network (ESN) 
benefit design at some point during their enrollment. 248,734 beneficiaries (86.0%) 
experienced changes in retail benefit design; 261,526 beneficiaries (90.4%) expe-
rienced changes in mail benefit design; 97,548 beneficiaries (33.7%) experienced 
changes in ESN benefit design. Among the retail changes, 44,134 beneficiaries 
(17.7%) had a change in tier structure [23,490 with an increased in number of tiers; 
20,644 with a decreased in number of tiers]. Additionally, 10,627 beneficiaries (4.3%) 
with a retail tier copayment converted to a coinsurance design; 5,301 beneficiar-
ies (2.1%) with retail coinsurance converted to a tier copayment design; 173,760 
beneficiaries (69.9%) stayed in tier copayment design but had a change in retail 
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objeCtives: To investigate the attitudes towards non-economic criteria to be 
used in resource allocation decisions in the health care sector among the Polish 
nurses. Methods: A cross-sectional survey with pen and paper interview was 
designed. A responder was asked person trade-off question such as how many Y’s 
would be equivalent to 10 X’s. Characteristics of a hypothetical patient defined as 
X and Y varied in each of three decision making scenarios. Answers from a median 
responder were used for the estimation of disease severity and potential for health 
weights as well as aversion to inequalities in health. VAS scale was adopted. Cohen’s 
kappa coefficient and Fisher exact test were performed. Results: 100 nurses with 
on average of 15 years of professional experience were interviewed. In the first 
scenario, the utility gain was equal for both X and Y. The median responder chose 
10 and more Y to compensate for 10 X with a worse starting point. Half of partici-
pants valued health gain differently dependent on the baseline utility. In the second 
scenario, the median responder chose 10 Y to compensate for 10 X irrespective of 
X’s superior utility gain. Although X had a higher potential to benefit, only 32% of 
participants valued it more than Y. In the third scenario, the median responder 
required a greater number of subjects in program B to compensate for the lost of 
equality in the end health for both X and Y in program A. More than 65% of par-
ticipants valued health equality (program A) against greater health gain (program 
B). ConClusions: Among study participants, an aversion to inequalities in end 
health was the most common. Different weightings of health gain dependent on 
the disease severity were accepted by half of participants. Majority of responders 
did not consider potential to benefit in their allocation decision.
PHP89
a QualitatiVE analysis oF niCE tECHnology aPPraisals: iDEntiFying 
trEnDs anD CommonalitiEs in rEstriCtED anD non-rECommEnDED 
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objeCtives: The number of technologies appraised by NICE has been increas-
ing since 2007, with a steep increase between 2009 and 2010. Much of this can be 
attributed to the influx of specialty pharmaceuticals, particularly targeted oncol-
ogy therapies. Along with this increase in the number of appraisals, the rate of 
‘restricted recommendations’ and ‘non-recommendations’ has also escalated. 
Various meanings and interpretations of ‘restricted’ can be applied depending on 
the area in which the restriction is applied (e.g. patient sub-groups, line of therapy). 
This research sets out to identify recurring trends and commonalities behind prod-
ucts that have received a ‘restricted recommendation’ or ‘non-recommendation’ 
as well as standardize the term ‘restricted’ based on the impact of the appraisal on 
market access. Methods: NICE appraisals between January, 2001 and December, 
2013 was reviewed and analyzed through simple descriptive statistics. The content 
of the appraisals were closely reviewed to identify the criteria and key elements 
driving each decision. Results of this analysis were applied in standardizing the 
term ‘restricted’ in order to identify the implications of these restrictions on market 
access. Results: NICE appraised 176 technologies from January 2001 - December 
2013 (withdrawn appraisals and re-appraisal were not included in the analysis). 
Between the time periods of 2000-2007 and 2008-2013, the average number or 
appraisals a year nearly doubled. The rate of ‘restricted recommendation’ increased 
from 12% to 36% in the same time period and the number of ‘non-recommendations’ 
increased from 10% to 23%. ConClusions: Given the high cost and targeted regi-
men of specialty pharmaceuticals, (e.g. biologic oncology therapies), ability to dem-
onstrate cost-effectiveness in broad patient populations has become increasingly 
challenging, leading to higher rates of ‘restricted recommendations.’ Commonalities 
among technologies receiving ‘non-recommendations’ include use of unacceptable 
comparators, endpoints, and study durations.
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objeCtives: The objective of this study was to develop a conceptual framework 
to estimate potential consequences of IRP reforms by estimating the impact if a 
European country was to include Turkey into the set of countries that it uses to 
establish the reference price. Methods: Phase 1 consisted of obtaining evidence on 
the IRP countries using a literature review from 2011 to 2013 (WHO/HAI Systematic 
Review - May 2011) based on ECONLIT, MEDLINE and grey literature. Phase 2 con-
sisted of developing a conceptual framework and model database to summarize 
IRP designs, reference baskets, methods and updates. Model inputs for the product 
included prices, volume, and launch phase. Phase 3 consisted of building and testing 
the model from a manufacturer perspective with a variable time horizon up to 5 
years. Products from the epidermal growth factor receptor (EGFR) class were selected 
to estimate the potential effects of including Turkey into the reference basket used 
by EU countries to calculate reference rules. Results: Four peer-reviewed and a 
number of websites and white papers were identified discussing IRP related issues. 
A conceptual framework was designed considering 1) database of IRP country rules, 
2) product data, and 3) model input interface to conduct one-way sensitivity analysis 
of a simulated IRP reform. Inclusion of Turkey into the reference basket of various EU 
markets lead to large negative financial impacts for companies with EGFR products. 
The countries that lead to the largest impact were Romania and Greece. The second 
order effects such as countries that re-referenced Greece and Romania were larger 
over the 5-year time frame compared with the primary effects. ConClusions: 
The proposed conceptual framework may offer another tool to estimate the impact 
